October 26, 2021—The U.S. Federal Trade Commission’s (FTC’s) recently released Cigarette Report1 showed that the number of cigarettes sold increased from 202.9 billion in 2019 to 203.7 billion in 2020. […] Read more
In the past decade, targeting of the PD-1/PD-L1 checkpoint, with or without CTLA-4 targeting, has revolutionized cancer treatment. However, a significant proportion of patients with lung cancer still do not […] Read more
Two studies presented at the WCLC Congress 2021 include data that suggest the potential need to update the current TNM classification of lung cancers by implementing additional pathological elements to […] Read more
Value-based care is getting more attention in lung cancer thanks to two new programs offering significant rebates or full refunds should the therapeutic agent be ineffective or intolerable. Pfizer’s pilot […] Read more
In 2015, the World Health Organization (WHO) revised its 2004 classification of lung tumors to reflect the impact of genetic, clinical, and radiologic advances in the field.1 Among the revisions […] Read more
Treatment options for patients with malignant pleural mesothelioma (MPM) are limited. While patients with advanced or inoperable MPM are traditionally treated with cisplatin and pemetrexed as a standard first-line treatment, […] Read more
Although low-dose CT scans enable the detection of very small lung nodules in individuals who face a high risk of developing lung cancer, it is often impossible to quickly determine […] Read more
Despite the past decade’s accomplishments in identifying the genetic drivers of NSCLC, the complexity of these cancers continues to create barriers to effective targeted treatment. Finding strategies capable of overcoming […] Read more
Atezolizumab Approved for Adjuvant NSCLC Therapy for Patients with Stage II-IIIA Disease, PD-L1 ≥ 1%
October 15, 2021— Based on the results of phase III IMpower010, atezolizumab was approved by the U.S. Food and Drug Administration (FDA) as adjuvant treatment after surgery and chemotherapy for […] Read more
It is a trend many years in the making, but the time is ripe to fix the increasing problems with clinical trial consent documentation. The word count and complexity of […] Read more